Davis Polk advised Credit Suisse Securities (USA) LLC, Citigroup Global Markets Inc. and Canaccord Genuity Inc. as joint book-running managers and representatives of the underwriters of an approximately $90 million SEC-registered offering of 16,375,000 shares of common stock of Synergy Pharmaceuticals Inc. Cantor Fitzgerald & Co. acted as co-manager of the offering. The common stock is listed on the Nasdaq Global Market under the symbol “SGYP.”
Based in New York, NY, Synergy Pharmaceuticals is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases.
The Davis Polk corporate team included partner Richard D. Truesdell Jr., associates Connor Kuratek, Liang Dong and Michael R. Newton and law clerk Nicholas J. Marricco. Partner Kathleen L. Ferrell and associate Ankur Dalal provided tax advice. The environmental team included counsel Loyti Cheng and law clerk Leah Cowdrey. The intellectual property team included associate David R. Bauer and law clerk Jansen A. S. Thurmer. Counsel Marcie A. Goldstein provided FINRA advice. Sorina Delia Lazar was the legal assistant on the transaction. Members of the Davis Polk team are based in the New York office.
